SCHEMBL7532072

SCHEMBL7532072

Fc1ccc(-c2nc(-c3ccc(Br)cc3)cs2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.73
RAB9A P51151 5/20 0.73
SMN1; SMN2 Q16637 5/20 0.73
LMNA P02545 3/20 0.73
AR P10275 1/20 0.73
CYP19A1 P11511 3/20 0.59
ALDH1A1 P00352 2/20 0.56
ALOX5 P09917 1/20 0.56
MAPT P10636 5/20 0.54
NPC1 O15118 3/20 0.54
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
NPSR1 Q6W5P4 2/20 0.53
SREBF2 Q12772 3/20 0.51
POLB P06746 1/20 0.51
GAA P10253 1/20 0.50
RECQL P46063 1/20 0.50
ATM Q13315 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
HDAC1 Q13547 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17014749 0.84 KDM4E (1.00) KDM4ERAB9ASMN1; SMN2LMNAAR
SCHEMBL28491325 0.84 KDM4E (0.75) KDM4ERAB9ASMN1; SMN2LMNAAR
SCHEMBL3603144 0.84 RAB9A (0.75) KDM4ERAB9ASMN1; SMN2LMNAAR
SCHEMBL14531231 0.84 KDM4E (0.75) KDM4ERAB9ASMN1; SMN2LMNAAR
SCHEMBL17336836 0.84 RAB9A (0.75) KDM4ERAB9ASMN1; SMN2LMNAAR
SCHEMBL7534771 0.83 KDM4E (0.69) KDM4ERAB9ASMN1; SMN2LMNAAR
SCHEMBL28822894 0.83 KDM4E (0.59) KDM4ERAB9ASMN1; SMN2LMNAAR
SCHEMBL28495695 0.83 KDM4E (0.73) KDM4ERAB9ASMN1; SMN2LMNAAR
SCHEMBL11456620 0.83 KDM4E (0.73) KDM4ERAB9ASMN1; SMN2LMNAAR
SCHEMBL28493960 0.83 SMN1; SMN2 (0.73) KDM4ERAB9ASMN1; SMN2LMNAAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111909110-A Preparation method of 2, 4-disubstituted thiazole compound 浙江工业大学 2020-11-10 CN disclosed
US-6380187-B2 FUNGICIDES YU DINGWEI TIM (US) 2002-04-30 US disclosed
US-20020002193-A1 Thiadiazole antifungal agents YU DINGWEI TIM (US) 2002-01-03 US disclosed
US-6281217-B2 ANTIFUNGAL ACTIVITY AGAINST A VARIETY OF FUNGI INCLUDING STRAINS WHICH HAVE PROVEN TO BE RESISTANT TO TREATMENT WITH KNOWN ANTIFUNGAL AGENTS SUCH AS FLUCONAZOLE. YU DINGWEI TIM (US) 2001-08-28 US disclosed
US-6277873-B1 CONTROLLING DRUG RESISTANT FUNGI YU DINGWEI TIM (US) 2001-08-21 US disclosed
US-20010000512-A1 Novel class of piperazino substituted thiazoles YU DINGWEI TIM (US) 2001-04-26 US disclosed
US-20010000177-A1 Novel class of thiomorpholino substituted thiazoles YU DINGWEI TIM (US) 2001-04-05 US disclosed
US-20010000178-A1 PYRIDYL SUBSTITUTED THIAZOLES YU DINGWEI TIM (US) 2001-04-05 US disclosed
US-6156776-A Diaryl substituted thiazoles useful in the treatment of fungal infections YU DINGWEI TIM (US) 2000-12-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010000177-A1 Novel class of thiomorpholino substituted thiazoles THUMPD1, ERG28, THOC2 KDM4E 4127/4885RAB9A 4242/4885SMN1; SMN2 4644/4885
US-20020002193-A1 Thiadiazole antifungal agents ERG28, NAT1, AADAC KDM4E 3332/4885RAB9A 3829/4885SMN1; SMN2 4461/4885
US-20010000512-A1 Novel class of piperazino substituted thiazoles ERG28, DPM1, NAT1 KDM4E 3274/4885RAB9A 3881/4885SMN1; SMN2 4712/4885
US-20010000178-A1 PYRIDYL SUBSTITUTED THIAZOLES PDXK, OXA1L, ERG28 KDM4E 3629/4885RAB9A 4224/4885SMN1; SMN2 4264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.